Clinical Trial Update: An Open-Label, Non-Comparative, Phase III Study of the Raf-Kinase Inhibitor BAY 43-9006 as a Subsequent to First-Line Therapy in Patients With Advanced Renal Cell Carcinoma [Phase 3]

View source ↗

Summary

Phase III, open-label, non-comparative study of BAY 43-9006 (sorafenib) as second-line therapy after first-line treatment in patients with advanced renal cell c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Nexavar (Sorafenib)

Snippet

Sponsor: Bayer | Conditions: Carcinoma, Renal Cell | Phase 3 | Status: COMPLETED